Free Trial
NYSE:BMY

Bristol Myers Squibb (BMY) Stock Price, News & Analysis

Bristol Myers Squibb logo
$47.49 +1.20 (+2.59%)
Closing price 03:59 PM Eastern
Extended Trading
$47.62 +0.13 (+0.28%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bristol Myers Squibb Stock (NYSE:BMY)

Key Stats

Today's Range
$46.17
$48.26
50-Day Range
$44.06
$50.68
52-Week Range
$39.35
$63.33
Volume
21.03 million shs
Average Volume
12.94 million shs
Market Capitalization
$96.65 billion
P/E Ratio
17.79
Dividend Yield
5.22%
Price Target
$58.00
Consensus Rating
Hold

Company Overview

Bristol Myers Squibb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

BMY MarketRank™: 

Bristol Myers Squibb scored higher than 98% of companies evaluated by MarketBeat, and ranked 6th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on 5 buy ratings, 13 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Bristol Myers Squibb has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bristol Myers Squibb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bristol Myers Squibb are expected to decrease by -9.64% in the coming year, from $6.74 to $6.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bristol Myers Squibb is 17.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.87.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bristol Myers Squibb is 17.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.31.

  • Price to Earnings Growth Ratio

    Bristol Myers Squibb has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bristol Myers Squibb has a P/B Ratio of 5.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bristol Myers Squibb's valuation and earnings.
  • Percentage of Shares Shorted

    1.66% of the float of Bristol Myers Squibb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bristol Myers Squibb has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • Dividend Leadership

    Bristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 5.35%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Bristol Myers Squibb has been increasing its dividend for 17 years.

  • Dividend Coverage

    The dividend payout ratio of Bristol Myers Squibb is 92.88%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 40.72% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.

  • Read more about Bristol Myers Squibb's dividend.
  • Percentage of Shares Shorted

    1.66% of the float of Bristol Myers Squibb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bristol Myers Squibb has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Bristol Myers Squibb has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 52 news articles for Bristol Myers Squibb this week, compared to 38 articles on an average week.
  • Search Interest

    137 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.
  • MarketBeat Follows

    Only 21 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bristol Myers Squibb insiders have bought 5,384.54% more of their company's stock than they have sold. Specifically, they have bought $202,215.00 in company stock and sold $3,687.00 in company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of Bristol Myers Squibb is held by insiders.

  • Percentage Held by Institutions

    76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bristol Myers Squibb's insider trading history.
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Stock News Headlines

A grave, grave error.
Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it.
See More Headlines

BMY Stock Analysis - Frequently Asked Questions

Bristol Myers Squibb's stock was trading at $56.56 at the start of the year. Since then, BMY shares have decreased by 16.0% and is now trading at $47.49.
View the best growth stocks for 2025 here
.

Bristol Myers Squibb Company (NYSE:BMY) posted its quarterly earnings results on Thursday, April, 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The business's revenue was down 5.6% on a year-over-year basis.
Read the conference call transcript
.

Shares of Bristol Myers Squibb split on the morning of Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Bristol Myers Squibb's Board of Directors initiated a stock buyback program on Thursday, December 7th 2023, which authorizes the company to repurchase $3,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 2.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

The following companies are subsidiaries of Bristol Myers Squibb: MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others.

Top institutional shareholders of Bristol Myers Squibb include Park National Corp OH, Stonebridge Capital Management Inc. and Harbor Investment Advisory LLC. Insiders that own company stock include Giovanni Caforio, David V Elkins, Samit Hirawat, Christopher S Boerner, Rupert Vessey, Theodore R Samuels II, Ann Powell, Phil M Holzer, Benjamin Hickey and Robert M Plenge.
View institutional ownership trends
.

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

Record date for 5/1 Dividend
4/04/2025
Ex-Dividend for 5/1 Dividend
4/04/2025
Last Earnings
4/24/2025
Dividend Payable
5/01/2025
Today
7/01/2025
Record date for 8/1 Dividend
7/03/2025
Ex-Dividend for 8/1 Dividend
7/03/2025
Next Earnings (Estimated)
7/31/2025
Dividend Payable
8/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:BMY
Employees
34,100
Year Founded
1887

Price Target and Rating

Average Stock Price Target
$58.00
High Stock Price Target
$73.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+22.3%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
22 Analysts

Profitability

Trailing P/E Ratio
17.74
Forward P/E Ratio
7.04
P/E Growth
1.37
Net Income
-$8.95 billion
Pretax Margin
12.82%

Debt

Sales & Book Value

Annual Sales
$48.30 billion
Cash Flow
$6.03 per share
Price / Cash Flow
7.87
Book Value
$8.08 per share
Price / Book
5.87

Miscellaneous

Outstanding Shares
2,035,080,000
Free Float
2,033,656,000
Market Cap
$96.52 billion
Optionable
Optionable
Beta
0.38

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NYSE:BMY) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners